Association for Accessible Medicines

05/12/2026

Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved American’s $467 billion—providing patients the health and financial outcomes necessary to thrive. https://accessiblemeds.org/resources/blog/2025-savingsreport

05/07/2026

brings together the leaders driving access and affordability in healthcare — and early registrants get the advantage.

Early Bird pricing is available for a limited time — giving you the best rate to attend the most important
conversations in the industry.

Why GRx+BIOSIMS?
Because this is where planning turns into action:
✅ Policy and regulatory concerns meet real-world impact
✅ Access challenges meet actionable solutions
✅ Industry leaders connect and collaborate
✅ You’ll leave with insights, connections, and strategies you can put to work immediately.

Plan Early. Save More. Lead the Conversation.
Early Bird rates won’t last so make your plans now.

Secure your spot & save: https://accessiblemeds.org/events/grxbiosims-2026/

05/04/2026

Patient organizations play a critical role in shaping regulatory conversations—but here at AAM, we realize that navigating FDA processes can often be complex.

Join Food and Drug Law Institute (FDLI) on June 16–17 to gain practical insights into working with the FDA and strengthening engagement strategies.

Learn more: https://www.fdli.org/2026/06/2026-essentials-of-working-with-fda-for-patient-organizations/

05/01/2026

Healthcare doesn’t stand still — and neither do the conversations that shape it.

The biggest ideas in policy, access, affordability, and innovation happen when the right people come together. That’s what these two events are built to do.

2026 brings leaders across the generics and biosimilars space together to tackle the forces shaping the future of medicines — from regulation to real-world impact. Get the latest information directly from FDA experts, while taking a deep dive into the legal and policy aspects of the industry during three days of networking, learning and fun!

Registration is now open with early bird discount! ➡️ https://grxbiosims.org

puts the focus on patient access — uniting healthcare leaders, advocates, and decision-makers to drive meaningful, lasting change.

Learn more ➡️ https://accessiblemeds.org/events/access-2027

Two conversations, both focused on what comes next.

04/21/2026

In 2024, & saved America’s patients and the U.S. healthcare system $467 billion—and $3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: https://accessiblemeds.org/resources/blog/2025-savings-report

04/08/2026

In the past decade, and medicines have saved the U.S. healthcare system $3.4 trillion. Still, threats to the sustainability of this essential industry remain. Policymakers must ACT NOW to streamline FDA processes, curb patent abuse, stop PBMs and Medicare policies from denying patient access, and rollback harmful federal policies – including IRA price controls – to safeguard the livelihood of America’s patients. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

04/03/2026

Get ready for 2026, November 2–4, in Rockville, MD.

GRx+Biosims™ 2026 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Get the latest information directly from Food and Drug Administration experts, gain insight into the latest policies impacting the industry, and acquire valuable knowledge to advance your professional development.

Learn more: https://accessiblemeds.org/events/grxbiosims-2026/

Registration opens soon.

03/18/2026

Reforming PBM business practices is a regulatory and ethical imperative.

At AAM, we are thankful Congress has recently taken concrete steps to curtail PBM business practices. But MORE needs to be done to realize substantial savings for America's patients.

Prescription medicine pricing and reimbursement processes must be governed by transparency and accountability--and allow for healthy competition. In many cases, this means prioritizing the lower-cost generic & biosimilar medicines that make up 90% of all prescriptions filled in the U.S.

PBMs were established to manage the high costs of prescriptions, but their current opaque practices often dismiss the value of generic & biosimilar medicines, favoring higher-priced brand drugs and increasing costs at the pharmacy counter.

Learn more:https://accessiblemeds.org/wp-content/uploads/2026/02/AAM-Issue-Brief-Reforming-PBMs-to-Unlock-Savings.pdf

03/12/2026